Table 2.
Tumor biopsies before and after pembrolizumab
| ID | Tumor CD19+ | Total | Tumor | TME | TIL | |||
|---|---|---|---|---|---|---|---|---|
| PD-L1+ (%) | PD-L1+ (%) | PD-L1+ (%) | Total PD-1+ (%) | Tumor PD-1+ (%) | T cells PD-1+ (%) | |||
| 01- pre | Positive | 20 | 20 | <1 | ND | ND | ND | Present |
| 04-pre | Positive | 10 | 10 | <1 | 5 | <1 | 5 | Present |
| 05-pre | Positive | 50 | <1 | 50 | 5 | <1 | 5 | Present |
| 05-post | ND | 40 | <1 | 40 | 10 | <1 | 10 | Present |
| 06-pre | Positive | 5 | 5 | <1 | <1 | <1 | <1 | Absent |
| 06-post | ND | 10 | 10 | <1 | <1 | <1 | <1 | Absent |
| 07-pre | Positive | 80 | 80 | <1 | 5 | <1 | 5 | Present |
| 07-post | Positive | 50 | 50 | <1 | 10 | <1 | 10 | Present |
| 10-pre | Positive | 5 | 5 | <1 | <1 | <1 | <1 | Absent |
| 11-pre | Positive | <1 | <1 | <1 | 5 | <1 | 5 | Present |
| 12-pre | Positive | <1 | <1 | <1 | 5 | <1 | 5 | Present |
| 13-pre | Positive | 10 | 10 | <1 | 10 | 5 | 5 | Present |
Patient 02 had cytology with immunohistochemistry confirming presence of lymphoma; however, the above was not performed.
ND, not performed; TIL, tumor infiltrating CD3+ T cells.